MEDPACTO
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-type I receptor (TRI) that is currently in phase II clinical trials with global pharmaceutical companies such as Merck and AstraZeneca, is the leading drug candidate.
MEDPACTO
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2013-06-19
Address:
Seocho, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.medpacto.com
Total Employee:
51+
Status:
Active
Contact:
+82 2 6938 0200
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Korea Telecom Cafe24 DNS SK Broadband
Similar Organizations
Geno Biotech
Geno Biotech is a pioneer in the field of precision medicine and is the first biotech company
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Current Employees Featured
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-24 | MedPacto Hires Global Clinical Expert Timothy R. Allen as Executive Vice President |
Official Site Inspections
http://www.medpacto.com Semrush global rank: 3.92 M Semrush visits lastest month: 3.23 K
- Host name: 183.111.138.201
- IP address: 183.111.138.201
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "MedPacto"
MedPacto
MedPacto receives IND approval from the Ministry of Food and Drug Safety to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma. Feb 16, 2023. The …See details»
MedPacto
MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in …See details»
MedPacto - Crunchbase Company Profile & Funding
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring …See details»
MedPacto - LinkedIn
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the ...See details»
MedPacto, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jan 23, 2025 About MedPacto MedPacto (KOSDAQ: 235980) is a South Korean biomarker-driven drug discovery and development company specializing in innovative therapies for …See details»
MedPacto 2025 Company Profile: Stock Performance
MedPacto General Information Description. MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting …See details»
MedPacto - Funding, Financials, Valuation & Investors - Crunchbase
Dec 19, 2019 MedPacto is a genome-based drug discovery and clinical-stage biotechnology company. New. Resources. Advanced Search. Start Free Trial ... Experience the new …See details»
MedPacto - Overview, News & Similar companies | ZoomInfo.com
Nov 8, 2023 MedPacto's expertise lies in utilizing genome-based methods to identify novel targets and to develop first-in-class and best-in-class drugs. MedPacto is based in Suwon, …See details»
MedPacto, Inc.:Company Profile & Technical Research,Competitor …
MedPacto, Inc. is a company that provides Kidney fibrosis, Drug discovery, Medicine and more. MedPacto, Inc. is headquartered in South Korea . MedPacto, Inc. was founded in 2013. …See details»
Organization: MedPacto - Cbonds.com
MedPacto. Information about the issuer. News and credit ratings. . ... Organization name. MedPacto, Inc. Country name. Republic of Korea Country of registration-Industry. …See details»
MedPacto - Products, Competitors, Financials, Employees, …
MedPacto is a drug discovery and development company that develops therapeutics targeting cancer and autoimmune diseases. Use the CB Insights Platform to explore MedPacto's full …See details»
MedPacto
Career. 2021-current Founder/CSO, MedPacto Therapeutics, USA; 2016-current CEO/FOUNDER, MedPacto, Inc. Korea; 2018-current Founder/Board Director, Celloram Inc. …See details»
MedPacto - businessabc.net
Feb 25, 2025 MedPacto was founded in 2012 by a range of scientists and clinical experts in cancer and translational medicine. Early discoveries have translated into preclinical and …See details»
MedPacto - Contacts, Employees, Board Members, Advisors
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company. New. Resources. Advanced Search. ... Experience the new Crunchbase, powered by AI . …See details»
Medpacto Inc. - BioCentury Company Profiles - BCIQ
Apr 14, 2023 Medpacto Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Vactosertib by MedPacto for Metastatic Colorectal Cancer: …
Dec 30, 2024 MedPacto overview MedPacto, a subsidiary of Theragen Etex Co Ltd, is a biotechnology company that discovers and develops therapies to treat cancer and …See details»
Chime Biologics and Korean Listed Company MedPacto Form …
Oct 28, 2024 About MedPacto MedPacto (KOSDAQ: 235980) is a South Korean biomarker-driven drug discovery and development company specializing in innovative therapies for …See details»
MedPacto, Samsung Biologics ink CDMO deal for solid cancer drug
Apr 15, 2021 MedPacto, a biomarker-based developer of innovative new drugs, said Wednesday that it has signed an agreement with Samsung Biologics to develop and …See details»
MedPacto
MedPacto’s anticancer assets are developed to treat based on biomarker expression, which is agnostic to any specific tumor tissue type, and to combine with various therapeutic options. …See details»
What are Healthcare Management Service Organizations (MSO)?
1 day ago A healthcare management services organization is an administrative tool that enables enhanced checks and controls over patient information and other data unique to a specific …See details»